A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial)

被引：1
|
作者：
Mirza, M. R. [1 ,2 ]
Monk, B. J. [3 ]
Oza, A. [4 ]
Mahner, S. [5 ,6 ]
Redondo, A. [7 ,8 ]
Fabbro, M. [9 ,10 ]
Ledermann, J. [11 ,12 ]
Lorusso, D. [13 ,14 ]
Vergote, I. B. [15 ,16 ]
Rosengarten, O. [17 ,18 ]
Berek, J. [19 ]
Herrstedt, J. [20 ,21 ]
Tinker, A. V. [22 ]
Dubois, A. [23 ,24 ]
Gonzalez Martin, A. [25 ,26 ]
Follana, P. [27 ,28 ]
Benigno, B. [29 ]
Rimel, B. J. [30 ]
Agarwal, S. [31 ]
Matulonis, U. [32 ]
机构：
[1] NSGO, Dept Oncol 5073, Copenhagen, Denmark
[2] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark
[3] Univ Arizona, Canc Ctr Phoenix, Dept Oncol, Phoenix, AZ USA
[4] Univ Hlth Network, Dept Oncol, Toronto, ON, Canada
[5] AGO, Dept Gynegol, Hamburg, Germany
[6] Univ Munich, Hamburg, Germany
[7] GEICO, Dept Oncol, Madrid, Spain
[8] Univ Hosp, Madrid, Spain
[9] GINECO, Dept Oncol, Montpellier, France
[10] Inst Canc Montpellier, Montpellier, France
[11] NCRI, Dept Med Oncol, London, England
[12] UCL, London, England
[13] MITO MaNGO, Dept Gynecol Oncol, Milan, Italy
[14] Fdn IRCCS Natl Canc Inst, Milan, Italy
[15] BGOG, Dept Obstet & Gynecol, Leuven, Belgium
[16] Univ Leuven, Leuven, Belgium
[17] ISGO, Dept Gynecol Oncol, Jerusalem, Israel
[18] Shaare Zedek Med Ctr, Jerusalem, Israel
[19] Stanford Womens Canc Ctr, Dept Oncol, Stanford, CA USA
[20] NSGO, Dept Oncol, Odense, Denmark
[21] Odense Univ Hosp, Odense, Denmark
[22] British Columbia Canc Agcy, Dept Med, Vancouver, BC, Canada
[23] AGO, Dept Oncol, Essen, Germany
[24] Kliniken Essen Mitte, Essen, Germany
[25] GEICO, Med Oncol Dept, Madrid, Spain
[26] MD Anderson Canc Ctr Madrid, Madrid, Spain
[27] GINECO, Dept Med Oncol, Nice, France
[28] Ctr Antoine Lacassagne, Nice, France
[29] Univ Gynecol Oncol, Dept Gynecol Oncol, Atlanta, GA USA
[30] Cedars Sinai Med Ctr, Dept Obstet & Gynecol, West Hollywood, CA USA
[31] Tesaro Inc, Dept Med Affairs, Waltham, MA USA
[32] Dana Farber Canc Inst, Dept Gynecol Oncol, Boston, MA 02115 USA
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw435.26
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA3_PR
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial
    Mirza, Mansoor Raza
    Lundqvist, Elisabeth Avail
    Birrer, Michael
    Christensen, Rene DePont
    Nyvang, Gitte-Bettina
    Malander, Susanne
    Anttila, Maarit
    Werner, Theresa L.
    Lund, Bente
    Lindahl, Gabriel
    Hietanen, Sakari
    Peen, Ulla
    Dimoula, Maria
    Roed, Henrik
    Knudsen, Anja Or
    Staff, Synnove
    Vistisen, Anders Krog
    Bjorge, Line
    Maenpaa, Johanna U.
    LANCET ONCOLOGY, 2019, 20 (10): : 1409 - 1419
  • [32] Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial
    Kurtz, Jean-Emmanuel
    Pujade-Lauraine, Eric
    Oaknin, Ana
    Belin, Lisa
    Leitner, Katharina
    Cibula, David
    Denys, Hannelore
    Rosengarten, Ora
    Rodrigues, Manuel
    de Gregorio, Nikolaus
    Garcia, Jeronimo Martinez
    Petru, Edgar
    Kocian, Roman
    Vergote, Ignace
    Pautier, Patricia
    Schmalfeldt, Barbara
    Gaba, Lydia
    Polterauer, Stephan
    Reynier, Marie-Ange Mouret
    Sehouli, Jalid
    Churruca, Cristina
    Selle, Frederic
    Joly, Florence
    D'Hondt, Veronique
    Bultot-Boissier, Emilie
    Lebreton, Coriolan
    Lotz, Jean-Pierre
    Largillier, Remy
    Heudel, Pierre-Etienne
    Heitz, Florian
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (30) : 4768 - +
  • [33] A phase I study of bevacizumab in combination with niraparib in patients with platinum-sensitive epithelial ovarian cancer: The ENGOT-OV24/AVANOVA1 trial.
    Mirza, Mansoor Raza
    Mortensen, Christiane Ehlers
    Christensen, Rene dePont
    Christoffersen, Louise
    Westergaard, Mia
    Boufercha, Louisa
    Birrer, Michael
    Avail-Lundqvist, Elisabeth
    Bjorge, Line
    Maenpaa, Johanna Unelma
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [34] Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
    Poveda, Andres
    Floquet, Anne
    Ledermann, Jonathan A.
    Asher, Rebecca
    Penson, Richard T.
    Oza, Amit M.
    Korach, Jacob
    Huzarski, Tomasz
    Pignata, Sandro
    Friedlander, Michael
    Baldoni, Alessandra
    Park-Simon, Tjoung-Won
    Tamura, Kenji
    Sonke, Gabe S.
    Lisyanskaya, Alla
    Kim, Jae-Hoon
    Filho, Elias Abdo
    Milenkova, Tsveta
    Lowe, Elizabeth S.
    Rowe, Phil
    Vergote, Ignace
    Pujade-Lauraine, Eric
    LANCET ONCOLOGY, 2021, 22 (05): : 620 - 631
  • [35] Olaparib Tablets as Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a BRCA1/2 Mutation (SOLO2/ENGOT-Ov21): A Final Analysis of a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial
    Poveda, Andres
    Floquet, Anne
    Ledermann, Jonathan A.
    Asher, Rebecca
    Penson, Richard T.
    Oza, Amit M.
    Korach, Jacob
    Huzarski, Tomasz
    Pignata, Sandro
    Friedlander, Michael
    Baldoni, Alessandra
    Park-Simon, Tjoung-Won
    Tamura, Kenji
    Sonke, Gabe S.
    Lisyanskaya, Alla
    Kim, Jae-Hoon
    Filho, Elias Abdo
    Milenkova, Tsveta
    Lowe, Elizabeth S.
    Rowe, Phil
    Vergote, Ignace
    Pujade-Lauraine, Eric
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2021, 76 (09) : 535 - 536
  • [36] FOOD EFFECT SUB STUDY OF A PHASE 3 RANDOMIZED DOUBLE- BLIND TRIAL OF MAINTENANCE WITH NIRAPARIB, A POLY(ADP) RIBOSE POLYMERASE (PARP) INHIBITOR IN PLATINUM-SENSITIVE OVARIAN CANCER PATIENTS
    Moore, K. N.
    Zhang, Z.
    Agarwal, S.
    Burris, H. A.
    Patel, M.
    Martell, R. E.
    Kansra, V.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 475 - 475
  • [37] Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial
    Ledermann, Jonathan A.
    Embleton, Andrew C.
    Raja, Fharat
    Perren, Timothy J.
    Jayson, Gordon C.
    Rustin, Gordon J. S.
    Kaye, Stan B.
    Hirte, Hal
    Eisenhauer, Elizabeth
    Vaughan, Michelle
    Friedlander, Michael
    Gonzalez-Martin, Antonio
    Stark, Daniel
    Clark, Elizabeth
    Farrelly, Laura
    Swart, Ann Marie
    Cook, Adrian
    Kaplan, Richard S.
    Parmar, Mahesh K. B.
    LANCET, 2016, 387 (10023): : 1066 - 1074
  • [38] Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer
    Zhong, Lixian
    Anh Thu Tran
    Tomasino, Taylor
    Nugent, Elizabeth
    Smith, Judith A.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2018, 24 (12): : 1219 - 1228
  • [39] A randomized, double-blind, placebo-controlled multicenter phase 3 trial of niraparib maintenance treatment in patients with advanced ovarian cancer following frontline chemotherapy
    Martin, A. Gonzalez
    Rojas, L. A.
    Braly, P. S.
    Barter, J.
    O'Malley, D. M.
    Oza, A. M.
    Haggerty, A. F.
    Vulsteke, C.
    Provencher, D. M.
    Graybill, W.
    Li, Y.
    Malinowska, I. A.
    Mirza, M. R.
    Vergote, I.
    Pothuri, B.
    Monk, B. J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [40] OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
    Aghajanian, Carol
    Blank, Stephanie V.
    Goff, Barbara A.
    Judson, Patricia L.
    Teneriello, Michael G.
    Husain, Amreen
    Sovak, Mika A.
    Yi, Jing
    Nycum, Lawrence R.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) : 2039 - 2045
12345